Addex Therapeutics

Today, on World Stroke Day, we reflect on the millions affected by this terrible condition. Stroke is the leading cause of disability worldwide, resulting in motor paralysis, loss of sensory function, impaired autonomic functions, impaired cognition leading to deficits in communication, attention and memory. Treatments are urgently needed to help stroke patients recover and retrain their sensory functions. At Addex Therapeutics, we are evaluating if modulating the glutamate receptor subtype 5 receptor pathway could lead to an effective therapy. Be #greaterthan #stroke #allostericmodulator #mGlu5 #glutamatereceptor

Today we announced our half-year and Q2 2024 financial results. Our CEO, Tim Dyer, and Head of Translational Science, Mikhail Kalinichev, will host a conference call later today at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to provide an update on business progress and a review of the Addex pipeline. #allostericmodulators #drugdevelopment #financialresults https://lnkd.in/eG-HfVNk

Congratulations to Karuna Therapeutics / Bristol Myers Squibb for the #FDAapproval of Cobenfy, the first new treatment for #schizophrenia approved in decades! Cobenfy treats schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors. Our spin-out company, Neurosterix, is developing an M4 specific positive #allostericmodulator. We believe this mechanism could indirectly modulate dopamine levels and induce antipsychotic activity without peripheral muscarinic side-effects seen with direct agonists.

Our CEO, Tim Dyer, will be attending the 24th Annual Biotech in Europe Forum, #Sachs_BEF (25 – 26 September) in Basel. If you’re interested in hearing about Addex Therapeutics and our pipeline of #allostericmodulators for #neurologicaldisorders, contact ir@addextherapeutics.com. Sachs Associates

We announced today that our provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023, as well as first quarter 2024 primarily due to the sale of part of our business to Neurosterix. There was a net gain of CHF 9.8 million for the six-month period ended June 30, 2024 compared to a net loss of CHF 5.1 million in the same period last year. Join us on September 30, 2024, for a complete Half-Year 2024 Financial Results review. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will host a conference call and webcast at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) that day to discuss the financial results and provide a business update on our #allostericmodulator pipeline. https://lnkd.in/dbdZddTZ 

Next week, our CEO, Tim Dyer, will be attending the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference in New York City. A pre-recorded Addex corporate presentation will be available to view on-demand from 07:00 EDT on Monday, September 9, 2024, via the following webcast link and subsequently on the Addex website events page. https://lnkd.in/eXSRPu3M Mr Dyer will be available for one-on-one meetings during the conference. To schedule a meeting, please contact us at IR@addexpharma.com. #allostericmodulators #drugdevelopment https://lnkd.in/e8aAtM3i

We are proud to announce that Indivior has selected clinical candidates from our #GABAB positive #allostericmodulator (PAM) research collaboration. Indivior is developing its candidate in substance use disorder and is responsible all future development. As part of the agreement, Addex Therapeutics has selected a compound to advance independently for the treatment of chronic #cough. #drugdiscovery #pharmapartnering https://lnkd.in/eQ3WfBgc

Data from studies in models of chronic #cough, which will be presented at the Thirteenth London International Cough Symposium (13th LICS) on July 19, showed that our #GABAB positive #allostericmodulator exhibited robust antitussive efficacy, combined with reduced centrally-mediated side-effects and improved tolerability in comparison to #baclofen. We believe that such a compound has the potential to become a best-in-class treatment for chronic cough. https://lnkd.in/eveNWaAf

Our Head of Translational Science, Dr. Mikhail Kalinichev, will present data on our GABAB positive #allostericmodulator #chroniccough program at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K. His presentation is scheduled for 12:00 CEST / 11:00 BST, on Friday July 19, 2024 in the Huxley Building. https://lnkd.in/en7naFDn

Today we announced our Q1 2024 financial results. Our CEO, Tim Dyer, and Head of Translational Science, Mikhail Kalinichev, will host a conference call later today at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to provide an update on business progress and a review of the Addex pipeline. #allostericmodulators #drugdevelopment #financialresults https://lnkd.in/dsNymquj